Novel composite health assessment risk model for older allogeneic transplant recipients: BMT-CTN 1704 Journal Article


Authors: Sorror, M. L.; Saber, W.; Logan, B.; Geller, N.; Bellach, A.; Kou, J.; Wood, W.; McCarty, J. M.; Knight, T. G.; Runaas, L.; Johnston, L.; Walston, J.; Nakamura, R.; Jarrett, L.; Mishra, A.; Uberti, J.; Dahi, P. B.; Saultz, J. N.; McCurdy, S. R.; Morris, L. E.; Imus, P. H.; Hogan, W. J.; Nadiminti, K.; Bhatt, V. R.; Olin, R.; Maakaron, J.; Sobecks, R.; Wall, S. A.; Mattila, D.; Protz, B.; Devine, S. M.; Horowitz, M. M.; Artz, A. S.
Article Title: Novel composite health assessment risk model for older allogeneic transplant recipients: BMT-CTN 1704
Abstract: Allogeneic hematopoietic cell transplantation (allo-HCT) is potentially curative for older adults with hematologic malignancies. Concerns on nonrelapse mortality (NRM) in older adults limit allo-HCT utilization. We executed a prospective, observational study BMT-CTN 1704 (Blood and Marrow Transplant Clinical Trials Network) enrolling allo-HCT recipients aged ≥60 years from 49 centers in the United States. We analyzed associations between 13 measurements of older adult health and NRM within 1 year to construct a comprehensive health assessment risk model (primary-CHARM) using multivariate Fine-Gray model and grouped penalized variable selection. Two machine learning (ML) models (Cox and pseudovalue boosting) were also explored. Models’ performances were compared using area under the curve (AUC), with bootstrap and cross-validation sampling to correct for optimism, decision curve analysis (DCA), calibration, and Brier scores. Among 1105 patients with median age of 67 (range, 60-82) years who received allo-HCT, NRM was 14.4% and overall survival (OS) 71.7% at 1 year. Factors statistically selected for inclusion in primary-CHARM were higher comorbidity burden, lower albumin, higher C-reactive protein, older age, higher weight-loss percentage, lower patient-reported performance score, and cognitive impairment. Primary-CHARM scores were independently associated with higher NRM (hazard ratio [HR], 2.72; P < .0001) and worse OS (HR, 2.09; P < .0001). Bootstrap bias–corrected AUC for primary-CHARM was 0.591. Comparing primary-CHARM with HCT-comorbidity index and 2 ML-CHARM models, calibration, Brier score, and DCA analysis favored primary-CHARM. Primary-CHARM, with mostly simple and readily available parameters, risk stratifies older adults for allo-HCT. Adopting primary-CHARM in practice may promote broader use of HCT by quantifying risk and enhance the design of strategies to improve outcomes. This trial was registered at www.ClinicalTrials.gov as #NCT03992352. © 2025 American Society of Hematology. All rights reserved.
Keywords: adult; controlled study; aged; major clinical study; overall survival; mortality; area under the curve; outcome assessment; follow up; c reactive protein; incidence; cohort analysis; hematopoietic stem cell transplantation; retrospective study; prediction; risk factor; risk assessment; confidence interval; body mass; hematologic malignancy; myelodysplastic syndrome; proportional hazards model; comorbidity; graft versus host reaction; allogeneic hematopoietic stem cell transplantation; hazard ratio; kaplan meier method; graft recipient; longitudinal study; sample size; hematocrit; demographics; acute myeloid leukemia; cancer prognosis; charlson comorbidity index; human; male; female; article
Journal Title: Blood Advances
Volume: 9
Issue: 13
ISSN: 2473-9529
Publisher: American Society of Hematology  
Date Published: 2025-07-08
Start Page: 3268
End Page: 3280
Language: English
DOI: 10.1182/bloodadvances.2025015793
PUBMED: 40101246
PROVIDER: scopus
PMCID: PMC12246602
DOI/URL:
Notes: Article -- Source: Scopus
Altmetric
Citation Impact
BMJ Impact Analytics
MSK Authors
  1. Parastoo Bahrami Dahi
    304 Dahi